1. Home
  2. KBH vs CRSP Comparison

KBH vs CRSP Comparison

Compare KBH & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KB Home

KBH

KB Home

N/A

Current Price

$52.94

Market Cap

3.8B

ML Signal

N/A

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

N/A

Current Price

$46.52

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KBH
CRSP
Founded
1957
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.4B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
KBH
CRSP
Price
$52.94
$46.52
Analyst Decision
Hold
Buy
Analyst Count
12
17
Target Price
$61.70
$70.29
AVG Volume (30 Days)
846.1K
2.0M
Earning Date
03-24-2026
05-05-2026
Dividend Yield
1.96%
N/A
EPS Growth
N/A
N/A
EPS
6.15
N/A
Revenue
$4,547,002,000.00
$289,590,000.00
Revenue This Year
N/A
$1,082.59
Revenue Next Year
$6.00
$87.74
P/E Ratio
$8.29
N/A
Revenue Growth
N/A
9169.85
52 Week Low
$49.70
$30.06
52 Week High
$68.71
$78.48

Technical Indicators

Market Signals
Indicator
KBH
CRSP
Relative Strength Index (RSI) 35.75 38.46
Support Level $50.07 N/A
Resistance Level $56.50 $60.63
Average True Range (ATR) 1.51 2.32
MACD -0.35 -0.84
Stochastic Oscillator 29.92 10.48

Price Performance

Historical Comparison
KBH
CRSP

About KBH KB Home

KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: